The Blogs: Israel prevented CF, not eliminated it

A recent social media thread has been circulating widely, claiming that “in ten years, Israel almost got rid of cystic fibrosis among newborns.” The implication is provocative: that through aggressive genetic screening and IVF policy, a nation can effectively end monogenic diseases.

The graphs are real. The decline in births of children with cystic fibrosis (CF) in Israel is real. But the story is far more nuanced—medically, ethically, and culturally—than a viral thread can convey.

And it says something profound about Israeli society.

The Israeli Model: Screening Before Pregnancy

In 2008, Israel introduced fully subsidized carrier screening for couples planning to have children. If one partner tested positive as a carrier for a condition such as cystic fibrosis, the other partner could be tested at no cost. If both were carriers—roughly 1 in 2,500 couples for CF—the state would fund IVF with preimplantation genetic testing (PGT).

The key distinction: This happens before pregnancy.

Couples who discover they are both carriers are given options:

Proceed naturally and accept the 25% risk per pregnancy
Use IVF with PGT to select embryos not affected by the disease
Consider other reproductive paths

Most Israeli couples choose prevention prior to conception rather than termination afterward. That cultural preference is not incidental. It reflects a deep societal comfort with assisted reproductive technology and a strong collective orientation toward preventive medicine.

Israel performs more IVF cycles per capita than any country in the world. This infrastructure did not emerge solely because of CF. It reflects a national ethos: children are central; medicine is proactive; the state subsidizes future health.

The result? A steady reduction in births of children affected by severe recessive diseases—including CF—without widespread reliance on second-trimester selective termination.

Contrast: The Sardinian Experience

The thread compares Israel with Sardinia’s historic approach to beta thalassemia. In the late 1970s, Sardinia implemented routine prenatal screening. When fetuses were found to have thalassemia major, termination was chosen in the vast majority of cases.

Two different mechanisms. Two similar epidemiologic outcomes.

But morally and culturally, they are not identical.

Israel’s model emphasizes:

Carrier screening before conception
IVF with embryo selection
State-funded reproductive autonomy

Sardinia’s model emphasized:

Screening during pregnancy
High rates of termination

These are not just medical strategies. They reflect different social values about when intervention should occur.

The Ethical Tension

Here is where the conversation becomes delicate.

When people say, “We could eliminate Huntington’s, cystic fibrosis, Fragile X,” they’re describing an epidemiological reality. If couples at risk consistently choose PGT to ensure their children won’t have these conditions, those conditions will become vanishingly rare. That’s not euphemism—it’s accurate description.

The moral question isn’t whether individual couples can make that choice. Most of us would say they can.

The harder question is what happens when millions of individual choices, facilitated by state infrastructure and normalized by social practice, reshape who gets born.

We must ask:

Are we reducing disease burden?
Or are we narrowing human genetic diversity?
Where is the line between prevention and selection?
Who decides which conditions warrant intervention?

In Israel, the system operates within strict medical criteria. But those criteria are contested territory.

Where Do We Draw the Line?

The current Israeli panel includes conditions like CF, Tay-Sachs, and familial dysautonomia—disorders that cause severe morbidity and often shortened lifespan.

But the boundaries are contested.

Consider:

Deafness-causing mutations: Some Deaf communities view deafness as cultural identity, not disease. Should carrier screening include it?

BRCA mutations: They raise cancer risk significantly but don’t guarantee disease. Is that “severe enough”?

Huntington’s disease: It doesn’t manifest until middle age. Should we select against it before conception?

Autosomal dominant polycystic kidney disease (ADPKD): This is where the line gets particularly blurry. ADPKD typically doesn’t cause symptoms until the 30s or 40s. Affected individuals often live full lives—careers, families, decades of health—before developing progressive kidney failure that may require dialysis or transplant. Treatment is improving. Many live into their 60s, 70s, or beyond with good quality of life.

As a nephrologist, I’ve cared for patients with ADPKD. I’ve seen the burden it creates—the slow loss of kidney function, the dietary restrictions, the dialysis sessions, the anxiety of waiting for transplant. If PGT could prevent that suffering, part of me thinks: of course we should offer it.

But I’ve also seen those same patients live rich, meaningful lives for decades before their kidneys failed. They’ve raised children, built careers, contributed to society. Would they have chosen to exist if their parents had known they carried the gene? I have to believe yes.

But would their parents have chosen to use PGT if it had been available and normalized? I honestly don’t know.

Treatable conditions: As CF treatment improves—median survival now exceeds 50 years in some countries—does it still qualify as severe enough to prevent?

These aren’t academic questions. They’re decisions that shape which lives come into being.

Right now in Israel, a committee of medical geneticists and ethicists makes these determinations. The process is deliberative and conservative. Conditions must meet strict criteria: early onset, severe impact, limited treatment.

But who sits at that table matters. Medical experts can assess disease burden. Disability advocates understand lived experience. Ethicists can frame principles. But affected communities should help define them.

The strength of Israel’s program is not just what it includes—it’s the ongoing debate about what it shouldn’t.

The View from Inside

The most important voices in this conversation are often the quietest: people living with cystic fibrosis.

For some, Israel’s screening program represents exactly what medicine should do—prevent suffering before it begins. For others, it carries a more complicated message: that lives like theirs are better prevented.

This is not hyperbole. It is the lived reality of disability in an age of genetic prevention.

The Israeli model deserves credit for distinguishing between preventing a condition and devaluing people who have it. But that distinction, however real in policy, can feel abstract to someone whose very existence is now classified as preventable.

We must hold both truths: CF causes real suffering. And people with CF are not suffering incarnate—they are whole human beings living meaningful lives.

Prevention is not rejection. But it can feel that way.

The question is whether that distinction—so clear in ethical theory—holds in lived experience. I don’t know the answer. But we must ask it honestly.

A Jewish Perspective on Prevention

Judaism has long embraced preventive medicine. The Rambam wrote that maintaining health is a religious obligation. Saving life—even potential life—is a core value.

At the same time, Judaism affirms that every human being is created b’tzelem Elokim—in the Divine image. Individuals living with CF, thalassemia, or other genetic disorders are not “mistakes to be corrected.” They are people of infinite worth.

This creates genuine tension. If preventing CF is a mitzvah—an act of compassion—does that imply that people with CF are somehow less than whole? Jewish law says no. A person’s infinite worth is not diminished by illness or disability. The Talmud teaches that one who saves a single life saves an entire world. It doesn’t specify: only if that life is healthy.

The challenge is holding both: preventing suffering is good. People who suffer are not less good.

Israel’s approach reflects this tension. It does not eliminate people. It offers families information and reproductive tools before conception.

That distinction is subtle but critical.

The Quiet Achievement

What Israel has accomplished is not a eugenics program. It is not forced policy. It is not mandated sequencing.

It is a public health strategy built on:

Voluntary participation
Universal access
State funding
Cultural acceptance of IVF
Early, pre-pregnancy intervention

And it worked. CF births declined significantly. So did Tay-Sachs decades earlier through community-based screening. Beta thalassemia rates fell in many populations through different methods.

Yet “voluntary” deserves examination.

When 98% of identified at-risk couples choose genetic testing, and the vast majority opt for PGT when both are carriers, is this purely individual choice? Or has screening become socially expected?

In Israel, where military service is universal and collective welfare is emphasized, the line between personal autonomy and social obligation can blur. Some couples report feeling they would be “irresponsible” not to screen—even before they understand what they’re screening for.

This is not coercion in the legal sense. No one is forced. But normative pressure operates in the space between mandate and freedom.

The question is not whether to abandon the program. It’s whether we acknowledge that when the state makes genetic selection universally accessible and statistically normative, “choice” exists within a framework that subtly guides it.

The Future: Power and Prudence

Whole genome screening for all couples is technically feasible within a decade. The cost is falling rapidly. Israel, with its centralized healthcare system and technological infrastructure, could implement it faster than most countries.

But should it?

As sequencing becomes routine, the list of detectable conditions will expand exponentially. ADPKD is just one example. We could screen for:

BRCA1/2 mutations (cancer predisposition, but not certainty)
Familial hypercholesterolemia (heart disease risk, but treatable with statins)
Lynch syndrome (colon cancer predisposition)
Factor V Leiden (clotting disorder, manageable with awareness)

All cause real problems. All are preventable through PGT. None are devastating in childhood. Many are increasingly treatable.

Where do we stop?

Technology advances faster than ethics. Policy must move slower than possibility.

We must preserve:

Informed consent
Guardrails around what qualifies as severe disease
Respect for disability communities
Avoidance of trait-based selection

Israel’s strength has never been technological prowess alone. It is the fusion of science with moral debate.

That debate must continue. And it must include voices beyond medical geneticists—disability advocates, ethicists, religious leaders, and most importantly, people living with the conditions we’re deciding whether to prevent.

Living With Paradox

Here is what Israel has achieved: a dramatic reduction in CF births through voluntary screening, state support, and early intervention. No coercion. No eugenics. Just information, access, and choice.

Here is what remains unresolved: As we expand our capacity to detect genetic variation, we must ask not only what we can prevent but who gets to decide what counts as prevention versus selection.

The Israeli model works because it operates within strict medical boundaries and deep cultural consensus. But that consensus itself raises questions.

Should the next generation of Israelis with CF—smaller in number, living in a society that successfully prevented most cases—feel grateful for medical progress? Or invisible in a world optimized against their existence?

Both can be true.

This is the paradox of genetic prevention: it can reduce suffering without devaluing those who suffer. It can embody compassion for future children without contempt for existing people. It can be medically sound and morally complex at the same time.

That uncertainty about conditions like ADPKD is exactly why these decisions can’t be left to technology alone. The capability to detect and prevent doesn’t automatically confer the wisdom to know when we should.

What Israel demonstrates is not that genetic diseases can be eliminated—it’s that societies must choose, with humility and care, how to wield the extraordinary power genetic knowledge confers.

The real measure of that power is not how many conditions we can prevent.

It’s whether we can prevent them while honoring the dignity of every person—born and unborn, healthy and ill, typical and rare.

That is the conversation we must continue.

And it requires not just scientists and policymakers, but people with disabilities, religious leaders, ethicists, and communities to shape together.

Because the future we’re building isn’t just about genes.

It’s about what kind of society we want to be.